Concentra Group Holdings Parent, Inc. (CON) — Current Report

AI-Powered SEC Filing Analysis

← All CON filings

Want the newest filings?

This analysis covers the filing from 2026-05-07. New 10-K, 10-Q and 8-K filings are analyzed the moment they are released — exclusively in the app.

Earlier Current Report filings

Filed: 2026-04-30
  • All three director proposals passed with strong shareholder support, with Vipin Gopal receiving 119.2M votes for (98.0% approval) and William K. Newton receiving 115.6M votes for (96.8% approval), indicating solid confidence in board leadership and continuity.
  • Marc R. Watkins, MD faced notably higher opposition with 21.8M votes against (18.2% dissent rate), suggesting some investor concern about this director's performance or qualifications that warrants monitoring in future periods.
  • Executive compensation received strong advisory approval with 114.2M votes for (95.6% support), indicating stockholders are satisfied with current pay practices and incentive structures for named executive officers.
  • PricewaterhouseCoopers LLP was ratified as auditor with overwhelming support (121.6M votes for, 99.7% approval) and zero broker non-votes, reflecting strong confidence in audit oversight and no audit-related controversies.
Filed: 2026-04-14
  • Concentra Group Holdings Parent, Inc. announced the retirement of its Executive Vice President and Chief Medical Officer, Dr. John Anderson, effective December 31, 2026. The company plans to enter into a Consulting Agreement with Dr. Anderson to support the transition of his responsibilities.
  • The company issued a press release on April 14, 2026, regarding Dr. Anderson's retirement, which indicates the event is being communicated to the market.
  • The departure of a C-level executive such as the Chief Medical Officer could signal changes in the company's strategic direction or operations, and investors should monitor any updates on the transition and the appointment of a new Chief Medical Officer.
Filed: 2026-02-26
  • Concentra Group Holdings Parent, Inc. reported its Q4 2025 and full-year 2025 financial results, indicating the company's performance during the period.
  • The company announced a cash dividend of $0.0625 per share, payable on March 19, 2026 to stockholders of record as of March 12, 2026.
  • The filing provides additional financial and operational details that may be of interest to investors in evaluating the company's performance and future prospects.
Filed: 2026-01-28
  • The company issued preliminary, unaudited results for Q4 and FY 2025, which suggests the company may be providing an earnings update or pre-announcement.
  • The company published a presentation and investor book in connection with the press release, indicating they are likely preparing for an investor event or earnings call.
  • As this is an 8-K filing, the information disclosed is likely material and could impact the stock price, depending on the actual results and company outlook.
Filed: 2026-01-12
  • Concentra Group Holdings Parent, Inc. reported preliminary, unaudited results for Q4 2025, which will be presented at the J.P. Morgan Healthcare Conference.
  • The company has not provided full financial results or guidance, indicating this is an interim operational update rather than a comprehensive earnings report.
  • Investors should look for additional details on Concentra's financial and operational performance when the company releases its full Q4 2025 results.

Other reports for Concentra Group Holdings Parent, Inc.

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.